Spots Global Cancer Trial Database for bladder urothelial carcinoma

Every month we try and update this database with for bladder urothelial carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers	NCT02989064	Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel...	Autologous gene...	18 Years - 75 Years	Adaptimmune
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	NCT02496208	Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer	NCT03473730	Bladder Urothel... Clear Cell Rena... Malignant Urina... Metastatic Kidn... Stage IV Renal ...	Biopsy Daratumumab Laboratory Biom... Metastasectomy Nephrectomy	18 Years -	M.D. Anderson Cancer Center
A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma	NCT05220124	Bladder Urothel...	Live Combined (...	18 Years -	Tianjin Medical University Second Hospital
Can VI-RADS/ADC Accurately Stage Bladder Cancer??	NCT04167631	MRI Contrast Me... Bladder Cancer Bladder Disease Bladder Neoplas... Bladder Urothel... Bladder Cancer ... Diagnoses Disea...	Multi-parametri...	18 Years -	Mansoura University
A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival	NCT03266900	Bladder Cancer Bladder Urothel...	re-TURBT 6 weeks BCG ins...	18 Years - 100 Years	University Health Network, Toronto
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	NCT02496208	Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy	NCT06263153	Bladder Urothel... Muscle Invasive... Stage II Bladde... Stage IIIA Blad...	Biospecimen Col... Computed Tomogr... Durvalumab Futibatinib Magnetic Resona... Radical Cystect...	18 Years -	Ohio State University Comprehensive Cancer Center
Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy	NCT04129606	Bladder Cancer Bladder Urothel... Trauma Injuries Perforation of ... Recurrence Tumo... Resection Margi... Seeding, Neopla...	Computed tomogr...	18 Years -	Mansoura University
Milademetan in Advanced/Metastatic Solid Tumors	NCT05012397	Solid Tumors Head and Neck C... Cholangiocarcin... Sarcoma Lung Adenocarci... Bladder Urothel... Stomach Adenoca... Breast Cancer I... Ovarian Carcino... Cervical Cancer Non Small Cell ... Gastric Cancer Biliary Tract C... Melanoma Pancreas Cancer MDM2 Gene Ampli... Testicular Germ... Adrenocortical ...	RAIN-32	18 Years -	Rain Oncology Inc
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)	NCT04574960	Bladder Cancer Bladder Urothel...	Gemcitabine Cisplatin Carboplatin	18 Years -	University Health Network, Toronto
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib	NCT05052372	Bladder Cancer Urothelial Carc... Transitional Ce... Platinum-Resist... Bladder Urothel... FGFR Mutation FGFR2 Gene Muta... FGFR3 Gene Muta... FGFR2 Amplifica... Locally Advance... Metastatic Urot... Refractory Blad... Refractory Blad...	Balversa	18 Years -	xCures
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer	NCT00238420	Bladder Urothel... Stage I Bladder... Stage II Bladde... Stage III Bladd...	Paclitaxel Radiation Thera... Trastuzumab	18 Years -	National Cancer Institute (NCI)
A Study of CDX-585 in Patients With Advanced Malignancies	NCT05788484	Non-small Cell ... Gastric Cancer Head and Neck C... Ovarian Cancer Primary Periton... Fallopian Tube ... Bladder Urothel... Colorectal Canc... Esophageal Canc... Hepatic Cancer Renal Cell Carc... Cholangiocarcin... Pancreatic Canc... Other Solid Tum...	CDX-585	18 Years -	Celldex Therapeutics
The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma	NCT01968928	Bladder Urothel...		20 Years - 80 Years	National Taiwan University Hospital
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies	NCT04440943	Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Primary Periton... Fallopian Tube ... Cholangiocarcin... Bladder Urothel... MSI-H Colorecta... Esophageal Canc... Hepatic Cancer Head and Neck C... Other Solid Tum...	CDX-527	18 Years -	Celldex Therapeutics
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies	NCT03329950	Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt...	CDX-1140 CDX-301 pembrolizumab Chemotherapy	18 Years -	Celldex Therapeutics
Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.	NCT06167356	Non Muscle Inva... Non-Muscle Inva... Non-Muscle Inva... Bladder Cancer Bladder Disease Bladder Neoplas... Bladder Urothel... Bladder Cancer ... Bladder Cancer ... Bladder Urothel... Bladder Urothel...		18 Years -	IRCCS San Raffaele
Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma	NCT03113266	Bladder Urothel...	humanized anti-...	18 Years -	Shanghai Junshi Bioscience Co., Ltd.
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib	NCT05052372	Bladder Cancer Urothelial Carc... Transitional Ce... Platinum-Resist... Bladder Urothel... FGFR Mutation FGFR2 Gene Muta... FGFR3 Gene Muta... FGFR2 Amplifica... Locally Advance... Metastatic Urot... Refractory Blad... Refractory Blad...	Balversa	18 Years -	xCures
Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy	NCT03039413	Bladder Urothel... Urothelial Carc...	Copper Cu 64 TP... Positron Emissi... Computed Tomogr...	18 Years - 75 Years	Thomas Jefferson University
Safety Analysis and Oncological Outcomes in HoLERT vs TURBT	NCT05833997	Bladder Urothel... Bladder Cancer	Monopolar Trans... Holmium Laser r...	18 Years - 80 Years	Instituto do Cancer do Estado de São Paulo
Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy	NCT04129606	Bladder Cancer Bladder Urothel... Trauma Injuries Perforation of ... Recurrence Tumo... Resection Margi... Seeding, Neopla...	Computed tomogr...	18 Years -	Mansoura University
En Bloc TURBT With Collins Loop vs Conventional TURBT	NCT05027412	Bladder Cancer Bladder Neoplas... Bladder Urothel... Bladder Cancer ... Urothelial Carc...	En bloc TURBT C... Conventional TU...	18 Years -	Hospital Universitario de Fuenlabrada
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy	NCT00072137	Bladder Adenoca... Bladder Squamou... Bladder Urothel... Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IV Bladde...	Recombinant Fow... Recombinant Fow... Therapeutic Con... Pharmacological... Laboratory Biom...	-	National Cancer Institute (NCI)
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer	NCT03775265	Bladder Urothel... Muscle Invasive... Stage II Bladde... Stage IIIA Blad...	Atezolizumab Biopsy of Bladd... Cisplatin Computed Tomogr... Cystoscopy Fluorouracil Gemcitabine Magnetic Resona... Mitomycin Quality-of-Life... Radiation Thera... Survey Administ... Transurethral R...	18 Years -	National Cancer Institute (NCI)
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies	NCT04440943	Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Primary Periton... Fallopian Tube ... Cholangiocarcin... Bladder Urothel... MSI-H Colorecta... Esophageal Canc... Hepatic Cancer Head and Neck C... Other Solid Tum...	CDX-527	18 Years -	Celldex Therapeutics
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies	NCT03329950	Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt...	CDX-1140 CDX-301 pembrolizumab Chemotherapy	18 Years -	Celldex Therapeutics
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers	NCT05296564	Sarcoma, Synovi... Sarcoma,Soft Ti... Melanoma Stage ... Triple Negative... Metastatic Canc... Non Small Cell ... Bladder Urothel... Neuroblastoma, ... Ovary Cancer	CYCLOPHOSPHAMID... Cyclophosphamid... HBI 0201-ESO TC... Aldesleukin	18 Years - 70 Years	Hadassah Medical Organization
Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy	NCT03039413	Bladder Urothel... Urothelial Carc...	Copper Cu 64 TP... Positron Emissi... Computed Tomogr...	18 Years - 75 Years	Thomas Jefferson University
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy	NCT00072137	Bladder Adenoca... Bladder Squamou... Bladder Urothel... Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IV Bladde...	Recombinant Fow... Recombinant Fow... Therapeutic Con... Pharmacological... Laboratory Biom...	-	National Cancer Institute (NCI)
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3	NCT05614739	Urinary Bladder... Neoplasm Metast... Ureteral Neopla...	LOXO-435 Pembrolizumab	18 Years -	Eli Lilly and Company
A Study of CDX-585 in Patients With Advanced Malignancies	NCT05788484	Non-small Cell ... Gastric Cancer Head and Neck C... Ovarian Cancer Primary Periton... Fallopian Tube ... Bladder Urothel... Colorectal Canc... Esophageal Canc... Hepatic Cancer Renal Cell Carc... Cholangiocarcin... Pancreatic Canc... Other Solid Tum...	CDX-585	18 Years -	Celldex Therapeutics
The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma	NCT01968928	Bladder Urothel...		20 Years - 80 Years	National Taiwan University Hospital
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers	NCT02989064	Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel...	Autologous gene...	18 Years - 75 Years	Adaptimmune
Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma	NCT04570410	Bladder Urothel...	primary focal r... Tislelizumab Gemcitabine plu...	18 Years - 75 Years	The First Affiliated Hospital with Nanjing Medical University
A Study of GV20-0251 in Patients With Solid Tumor Malignancies	NCT05669430	Solid Tumor, Ad... Refractory Canc... Bladder Urothel... Cholangiocarcin... Adenocarcinoma ... Endometrial Car... Head and Neck C... Cutaneous Melan... Non-small Cell ... Adenocarcinoma ...	GV20-0251 GV20-0251	18 Years -	GV20 Therapeutics
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3	NCT05614739	Urinary Bladder... Neoplasm Metast... Ureteral Neopla...	LOXO-435 Pembrolizumab	18 Years -	Eli Lilly and Company
Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy	NCT06170177	Muscle-Invasive... Muscle Invasive... Bladder Cancer ... Bladder Cancer ... Bladder Cancer ... Bladder Cancer ... Bladder Leiomyo... Bladder Cancer Bladder Cancer ... Bladder Cancer ... Bladder Cancer ... Bladder Cancer ... Bladder Urothel... Progression, Di... Urinary Diversi... Neobladder Radical Cystect...	Radical Cystect...	18 Years -	IRCCS San Raffaele

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: